Our products focus on a complete and systematic degradation of gluten immunogenic peptides
Our technology
Novel enzymatic solutions
Incomplete protein digestion
AMYRA's mode of action
The synergistic action of AMYRA’s exopeptidases is both important and unique since they are able to degrade proline-rich peptides, which are immunogenic for people with celiac disease and non-celiac gluten sensitivity and stable to degradation by naturally occurring digestion enzymes.
Amyra's unique mode of action
AMYRA’s unique exopeptidase therapy is able to digest proteolytically resistant peptides into single amino acids and dipeptides.
This mode of action has been demonstrated through extensive laboratory and clinical research with high-resolution analytical methods.
Proof of concept
AMYRA’s mode of action can be illustrated on the highly immunogenic α2-gliadin 33mer peptide. Through synergistic activity, AMYRA’s enzymes cleave either a single amino acid from the N-terminus (left side) of the 33mer peptide 1 3 or dipeptides in which a terminal amino acid is connected to proline (X-Pro) 2 .
This synergistic action results in the complete degradation of gluten-derived immunogenic peptides into harmless single amino acids and dipeptides 4 . The following illustration exemplifies the degradation of the gliadin 33mer:
